Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Neuropathic Pain Market Size Forecast: How Large Could The Market Become By 2030?
The market for neuropathic pain treatments has experienced significant expansion. Projections indicate a rise from $5.78 billion in 2025 to $6.2 billion in 2026, reflecting a compound annual growth rate of 7.3%. This past growth trajectory has been fueled by several factors, including the increasing incidence of diabetes, the early integration of antidepressant and anticonvulsant medications into treatment plans, heightened public and medical understanding of neuropathic pain, the advent of opioid-based therapeutic options, and the initial utilization of medical imaging for diagnostic purposes.
Anticipate a robust expansion within the neuropathic pain market, projected to reach $8.48 billion by 2030, reflecting a compound annual growth rate of 8.1% over the upcoming years. This upward trajectory is fueled by a confluence of factors, including a notable pivot towards non-opioid treatment modalities, an escalating need for tailored pain management strategies, a broader acceptance of complementary therapeutic interventions, heightened investments in groundbreaking diagnostic tools, and the progressive development of sophisticated multimodal treatment frameworks. Key developments shaping this period encompass the increasing embrace of integrated multimodal therapeutic approaches, a heightened demand for pain management solutions that bypass opioids, the growing integration of physical and psychological therapies, the enhancement of early detection capabilities through advanced imaging, and a concentrated effort on addressing diabetic neuropathy.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12922&type=smp
Neuropathic Pain Market Industry Drivers: What Is Driving Revenue Growth?
The expanding incidence of chronic pain is poised to stimulate advancement in the neuropathic pain market during the forecast period, as persistent discomfort lasting over three months, identified as chronic pain, impacts a considerable segment of individuals and detrimentally affects their overall well-being. This surge in chronic pain occurrences is attributed to demographic shifts such as an aging populace, instances of nerve damage, and long-term health conditions including diabetes. Treatments for neuropathic pain contribute to public health objectives by addressing nerve-related impairments, alleviating symptom severity, and enhancing patients’ functional capacity in their daily lives. Illustrating this trend, data released in November 2024 by the Centers for Disease Control and Prevention (CDC), a leading US health protection organization, indicated that in 2023, adult chronic pain prevalence stood at 24.3%, with high-impact chronic pain affecting 8.5% of adults, consequently representing 34.9% of those experiencing chronic pain; this data also highlighted disproportionately higher rates among women, American Indian and Alaska Native adults, and individuals aged 65 and above. Consequently, the escalating prevalence of chronic pain serves as a primary catalyst for the growth observed in the neuropathic pain market.
Neuropathic Pain Market Segment Landscape: Which Areas Lead Market Development?
The neuropathic pain market covered in this report is segmented –
1) By Treatment: Medications, Multimodal Therapy
2) By Diagnosis: Imaging, Blood Tests And Physical Examination
3) By Indication: Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy, Other Indications
4) By End User: Hospitals, Clinics, Home Healthcare, Ambulatory Surgical Centers, Other End Users
Subsegments:
1) By Medications: Anticonvulsants, Antidepressants, Opioids, Topical Treatments, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
2) By Multimodal Therapy: Combination Of Medications, Physical Therapy, Psychological Therapy, Lifestyle Modifications, Complementary Therapies
#Neuropathic Pain Market Growth Trends: What Is Influencing The Future Outlook?
Key players within the neuropathic pain sector are integrating artificial intelligence to elevate diagnostic precision, personalize therapeutic approaches, enable continuous patient observation, accelerate pharmaceutical development, and harness data-driven intelligence, all with the aim of improving patient results and optimizing pain management protocols. A notable illustration came in March 2023, when Nevro Corp., a medical device manufacturer headquartered in the United States, introduced its Senza HFX iQ spinal cord stimulation (SCS) system. This groundbreaking system leverages artificial intelligence (AI) to fine-tune pain alleviation specifically for each individual. Comprising the HFX iQ Implantable Pulse Generator (IPG), the HFX Trial Stimulator, a charger, and the HFX App, this integrated solution is engineered to address non-surgical back pain and painful diabetic neuropathy by dynamically adjusting to patient feedback and physiological responses. It incorporates a proprietary algorithm developed from substantial patient data, empowering patients to modify their pain relief regimen through a mobile application. The digital framework supporting this system facilitates the gathering of data and offers opportunities for future enhancements. Ultimately, this technology strives to boost the effectiveness of pain relief through a combination of reliability and individualized care, representing a substantial stride forward in SCS treatment.
Neuropathic Pain Market Industry Leaders And Market Competition
Major companies operating in the neuropathic pain market are Pfizer Inc., Johnson & Johnson Private Limited, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, GlaxoSmithKline Plc, Medtronic Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd, Boston Scientific Corporation, Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, Grünenthal GmbH, Lupin Ltd., Nevro Corp., InvaGen Pharmaceuticals Inc, Centaur Pharmaceuticals Pvt Ltd., Stimwave LLC, Novartis AG, Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Assertio Therapeutics Inc, NeuroMetrix Inc, OMRON Healthcare Co Ltd
Access The Complete Neuropathic Pain Market Report:
https://www.thebusinessresearchcompany.com/report/neuropathic-pain-global-market-report
Neuropathic Pain Market Regional Analysis: Which Region Leads By Revenue?
North Americawas the largest region in the neuropathic pain market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the neuropathic pain market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model